2,3,4,5,6-Pentamethyloxane

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧烷类
• 英文名称: 2,3,4,5,6-Pentamethyloxane
• 化学式: C₁₀H₂₀O
• 分子量: 156.26
• InChiKey: DLENZAYIWZDJFK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• ANTI-INFLUENZA AGENTS
  申请人：Von Itzstein Mark

  公开号：US20120202877A1

  公开（公告）日：2012-08-09

  The present invention relates to compounds that selectively inhibit influenza A virus group (1) sialidases and are therefore potential anti-influenza agents.

  本发明涉及选择性抑制流感A病毒群（1）唾液酸酶的化合物，因此是潜在的抗流感药物。
• FOAM COMPOSITIONS
  申请人：Gaco Western, LLC

  公开号：US20150299383A1

  公开（公告）日：2015-10-22

  Foam compositions are provided. The compositions are prepared from multi-functional acetoacetate esters and multi-functional amines or acrylates. The foam compositions can include one or more additives. The foam compositions can be used for home and commercial insulation, air sealing, sound proofing, structural improvement, and exterior roofing, among other applications. The foam compositions provide advantages of being isocyanate free and offer reduced exposure to isocyanate.

  提供泡沫组合物。该组合物由多功能乙酰乙酸酯和多功能胺或丙烯酸酯制备而成。泡沫组合物可以包含一个或多个添加剂。泡沫组合物可用于家庭和商业隔热、气密、隔音、结构改善和外部屋顶等应用。泡沫组合物具有无异氰酸酯的优点，并提供减少对异氰酸酯的暴露。
• Selective FKBP51 ligands for treatment of psychiatric disorders
  申请人：Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.

  公开号：US10246413B2

  公开（公告）日：2019-04-02

  The present invention relates to compounds having a selective FKBP51 ligand scaffold, pharmaceutically acceptable salts of these compounds and pharmaceutical compositions containing at least one of these compounds together with pharmaceutically acceptable carrier, excipient and/or diluents. Said selective FKBP51 ligand compounds can be used for prophylaxis and/or treatment of psychiatric disorders and neurodegenerative diseases, disorders and conditions.

  本发明涉及具有选择性 FKBP51 配体支架的化合物、这些化合物的药学上可接受的盐以及含有至少一种这些化合物和药学上可接受的载体、赋形剂和/或稀释剂的药物组合物。所述选择性 FKBP51 配体化合物可用于预防和/或治疗精神疾病和神经退行性疾病、紊乱和病症。
• GEL COMPOSITION FOR CELLULAR ADHESION INHIBITION
  申请人：Zong Xinhua

  公开号：US20070031498A1

  公开（公告）日：2007-02-08

  The invention includes compositions for inhibiting cellular adhesion, methods of preparation of such compositions, and methods for preventing cell adhesion at a surgical site comprising application of such compositions. The compositions generally comprise a cellular adhesion inhibitory agent, such as dextran sulfate, and a crosslinked hydrogel matrix, preferentially physically entrapping the adhesion inhibitory agent. The hydrogel matrix can include a first gel component, such as an electrophilically functionalized polyethylene glycol polymer, and at least one additional gel component, preferably nucleophilically functionalized, and preferentially selected from the group consisting of polyethylene glycol polymers, polypeptides, and polysaccharides. The compositions are useful for delivering the cellular adhesion inhibitory agent to a site in need of adhesion inhibition and providing either immediate or metered delivery of the inhibitory agent.
• Low activation energy dissolution modification agents for photoresist applications
  申请人：Allen David Robert

  公开号：US20070231734A1

  公开（公告）日：2007-10-04

  A photoresist composition including a polymer, a photo acid generator and a dissolution modification agent, a method of forming an image using the photoresist composition and the dissolution modification agent composition. The dissolution modification agent is insoluble in aqueous alkaline developer and inhibits dissolution of the polymer in the developer until acid is generated by the photoacid generator being exposed to actinic radiation, whereupon the dissolution modifying agent, at a suitable temperature, becomes soluble in the developer and allows the polymer to dissolve in the developer. The DMAs are glucosides, cholates, citrates and adamantanedicarboxylates protected with acid-labile ethoxyethyl, tetrahydrofuranyl, and angelicalactonyl groups.